Events News

‘No medicine is off limits’: US Chamber of Commerce says stricter import rules may deter fakes

12 November 2026 From GLP-1 drugs to cancer treatments, counterfeiters are exploiting supply chain weaknesses and AI to evade detection. The US chamber’s director of IP tells LSIPR why the fight against fakes is becoming more complex and what lies ahead.

How in-house teams can get more value from external counsel

9 November 2026

Regulatory and patent teams must align, say Amgen, Genentech, ORIC

5 November 2026

LSPN Fall 2026

‘No medicine is off limits’: US Chamber of Commerce says stricter import rules may deter fakes

Regulatory and patent teams must align, say Amgen, Genentech, ORIC

5 November 2026 Things can go “sideways pretty quickly” if the two sides of pharma protection are not communicating with each other, said a senior panel of industry counsel at LSPN Fall.

LSPN Fall: AI agents are taking on patent work. What’s left for lawyers?

4 November 2026 AI agents are no longer just helping patent lawyers with their workload. Some are now doing the work themselves. In-house counsel from Insitro, Illumina, 10x Genomics and Invenra discuss how much can be handed over and whether humans could be replaced.

In-house counsel rethink patent filing strategies as costs mount

3 November 2026 With budgets under pressure, counsel from Pfizer, ALX Oncology and BioMarin share how they are reassessing portfolios, trimming costs and prioritising key markets at LSPN Fall.

LSPN Europe 2026

‘Companies that don’t leverage AI will struggle to keep up’: Umicore IP chief

26 October 2026 Umicore’s Sean Alexander has seen the profession change considerably over three decades, but some of its biggest changes may still lie ahead. He tells LSIPR why AI is prompting difficult decisions, what he is no longer willing to pay external counsel for and why Europe is the place to watch.

WATCH: LEO Pharma head of IP rights on doing more with less

7 October 2026 With resources under pressure, the Danish company’s IP leader explains how AI, smarter prioritisation and close business ties can help IP teams boost their impact.

What's AI best at? In-house teams are still learning

2 October 2026 AI is helping legal and IP teams handle more work without adding headcount, but in-house counsel at LSPN Europe warn that knowing when not to rely on the technology is just as important as knowing how to use it.

WATCH: Genevant IP director on tackling UPC-EPO opposition divide

1 October 2026 With patent validity increasingly being fought over in both the UPC and EPO, Genevant Sciences’ Stephan Kutik talks to LSIPR about keeping parallel proceedings aligned and why teamwork matters.

LSPN Spring North America 2026

WATCH: Interview with Mythili Markowski, director at Regeneron

8 May 2026 LSIPR's senior reporter Marisa Woutersen speaks with Mythili Markowski of Regeneron on why new USPTO guidance is putting post-grant proceedings under the spotlight and how in-house teams are responding.

WATCH: Interview with Ben Doranz, president and CEO, Integral Molecular

4 May 2026 LSIPR's senior reporter Marisa Woutersen speaks with Ben Doranz of Integral Molecular, fresh from the stage at LSPN Boston after speaking at a panel session on challenges in antibody patent protection.